Rapid test of cerebrospinal fluid decreases time to diagnosis for brain tumors

"Unlike other forms of cancer that might get diagnosed at an outpatient center, most brain tumors and spinal cord tumors get diagnosed in the hospital, where patients often present with rapidly progressive deficits. This means that speed is of the essence," said corresponding author Ganesh Shankar, MD, PhD, a neurosurgeon and neurosurgical director of biospecimen banking for the Department of Neurosurgery at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system. "Because of the test we've developed, patients are now being diagnosed and treated without brain biopsies, which has also resulted in decreased time to diagnosis from 10 days to 2 days."

Shankar traces the origins of TetRS back almost a decade, to a time when researchers identified a handful of genes that were mutated in certain forms of brain cancer. In a paper published in 2015, the team showed that genetic mutations could be detected in tissue samples removed during surgery. The team further optimized TetRS and showed in 2021 that they could use the same approach on cerebrospinal fluid.

The new study puts TetRS to the test in the real world, where patients may present to the Emergency Department with an abnormal lesion that could be from a tumor or could be from something else. The research team wanted to ensure that TetRS could help lead to an accurate diagnosis faster, without leaving any room for a false positive result.

Shankar and colleagues designed TetRS to look for genetic signatures unique to brain cancer, including mutations in the MYD88, TERT promoter, IDH1, IDH2, BRAF and H3F3A genes. The team evaluated samples from 70 patients, 33 of whom were eventually diagnosed with neoplasms (abnormal tissue that can be benign or malignant). TetRS alone diagnosed six of the patients and, when combined with conventional methods, diagnosed an additional eight patients, for a total sensitivity of 42 percent. For the other 37 patients who were not diagnosed with neoplasms, TetRS returned zero false positives, for a specificity rate of 100 percent.

Using the rapid genotyping test eliminated the need for surgical brain biopsies for seven patients and significantly accelerated time to treatment for them, from an average of 12 days down to an average of 3 days.

The authors note that larger studies are needed to determine whether their findings are broadly applicable and what the clinical impact of earlier diagnosis and treatment will be for patients.

TetRS has been implemented as a clinically available test across Mass General Brigham, and Mass General Brigham Pathology has received and evaluated patient samples from MGH, Brigham and Women's Hospital and many other sites around the country.

"By working together across pathology, neuro-oncology and neurosurgery teams, we've developed an innovative, collaborative way to improve patient care," said co-author Deborah Forst, MD, of the Mass General Cancer Center. "The ability to rapidly detect tumor-related molecular variants in patients' spinal fluid samples has allowed us to promptly draw diagnostic conclusions through less invasive testing and to initiate individualized and potentially life-saving chemotherapies in rapid fashion."

Authorship: In addition to Shankar, Mass General Brigham authors include first author Mihir Gupta, Joseph D. Bradley, Elie Massaad, Evan J. Burns, N. Zeke Georgantas, Garrett E. Maron, Julie M. Batten, Aidan Gallagher, Julia Thierauf, Naema Nayyar, Amanda Gordon, SooAe S. Jones, Michelle Pisapia, Ying Sun, Pamela S. Jones, Fred G. Barker 2nd, William T. Curry, Rajiv Gupta, Javier M. Romero, Nancy Wang, Priscilla K. Brastianos, Maria Martinez-Lage, Deborah A. Forst, Brian V. Nahed, Tracy T. Batchelor, Lauren L. Ritterhouse, Justin T. Jordan, Jorg Dietrich, Daniel P. Cahill, Jochen K. Lennerz and Bob S. Carter. Additional authors include Kensuke Tateishi, Florian Iser, Tobias Kessler, and Matthew Meyerson.

Disclosures: Cahill and Shankar hold a patent pertaining to the use of peptide and locked nucleic acids as utilized in this study during the amplification of target DNA sequences (patent #US20170369939A1).

Funding: This work was supported by grants from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (1K08NS107634-01A1), The Darwin Project, the Brian D. Silber Memorial Fund, and National Cancer Institute (5U01CA230697).